After landing a historic FDA OK, Alnylam chief John Maraganore scores a big raise
It took more than 15 years all told, but last year Alnylam $ALNY finally made the big leap into commercializing the first of the RNAi drugs that it had been developing. And CEO John Maraganore and his top team at the bellwether biotech enjoyed a multimillion-dollar windfall on their success.
Maraganore isn’t competing for a place in the top 15 by any means. But he earned a compensation package worth a little more than $5 million — most of it in option awards — which is well under the $7.7 million earned by Emma Walmsley, who currently holds the bottom rung of the Big Pharma compensation ladder for 2018.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.